Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis
Open Access
- 25 January 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (4), 812-819
- https://doi.org/10.1093/rheumatology/kep457
Abstract
Objective. To determine the validity, reliability and responsiveness of the Work Productivity and Activity Impairment questionnaire in AS (WPAI:SpA). Methods. Baseline and Week-24 data from a randomized, double-blind study of adalimumab in patients with AS were used. Discriminative validity of WPAI:SpA absenteeism, presenteeism, overall work productivity loss and activity impairment scores was assessed relative to patient-reported outcomes: Bath AS Disease Activity Index (BASDAI), AS Quality of Life Questionnaire (ASQOL), Short-Form 36 Health Survey (SF-36), Physical and Mental Component Summaries (PCS and MCS, respectively) and Health Utilities Index Mark 3 (HUI-3). Responsiveness of the WPAI:SpA instrument was assessed for patients meeting the minimum clinically important differences (MCIDs) for ASQOL and BASDAI (i.e. quality of life and clinical responders, respectively) and quantified with standardized response mean (SRM) calculations. Results. Of 315 patients, 205 were employed at baseline. Patients with more severe AS (BASDAI > median) showed significantly greater impairment in work and daily activities than patients with lesser disease severity (P < 0.001). This trend was consistent for ASQOL, SF-36 PCS, SF-36 MCS and HUI-3. There were significant differences in WPAI:SpA scores for patients achieving BASDAI clinical response and ASQOL quality of life response vs non-responders. For responders, SRMs were large for work presenteeism, overall work impairment and activity impairment ( −0.86 to −1.29 for BASDAI; −0.89 to −1.18 for ASQOL) and small for absenteeism ( −0.25 for BASDAI; −0.31 for ASQOL). Conclusions. The WPAI:SpA is a valid, reliable and responsive tool for assessing work productivity for patients with AS. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/home, NCT00085644.This publication has 31 references indexed in Scilit:
- Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trialAnnals Of The Rheumatic Diseases, 2008
- Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo‐controlled trialArthritis Care & Research, 2006
- Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitisAnnals of Allergy, Asthma & Immunology, 1999
- Work, Classroom and Activity Impairment InstrumentsClinical Drug Investigation, 1996
- Multi-Attribute Preference FunctionsPharmacoEconomics, 1995
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984
- Economic Evaluation of Neonatal Intensive Care of Very-Low-Birth-Weight InfantsThe New England Journal of Medicine, 1983